<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613169</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000341</org_study_id>
    <nct_id>NCT02613169</nct_id>
  </id_info>
  <brief_title>Infant TB Infection Prevention Study</brief_title>
  <acronym>iTIPS</acronym>
  <official_title>Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled trial (RCT) of isoniazid (INH) vs. no INH to prevent Mycobacterium
      tuberculosis infection in HIV-exposed uninfected (HEU) infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to determine whether isoniazid (INH) reduces the risk of
      Mycobacterium tuberculosis (MTB) infection in HIV-exposed but uninfected (HEU) children, as
      well as to determine epidemiologic and immunologic correlates of MTB infection in HEU.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mycobacterium tuberculosis (MTB) infection</measure>
    <time_frame>at 12 months post randomization</time_frame>
    <description>Among HEU infants enrolled at approximately 6 weeks of age, compare the risk of acquiring MTB infection during 1 year of follow-up in infants randomized to receive INH vs. no INH using an interferon-gamma release (IGRA) assay to determine MTB infection status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events (SAE)</measure>
    <time_frame>Over 12 months after randomization</time_frame>
    <description>Number of infants with grade 3 or higher treatment-related adverse events as assessed by DAIDS Table for the Grading Severity of Pediatric Adverse Experiences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined outcome of MTB infection, TB disease, and death</measure>
    <time_frame>Over 12 months after randomization</time_frame>
    <description>Number of infants with a combined endpoint of MTB infection, TB disease, and death
MTB infection as measured by IGRA at 12 months post-enrollment
TB disease including microbiologically confirmed (culture or Xpert positive), or probable TB (clinical diagnosis).
Death of infant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Isoniazid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isoniazid (INH) ~10 mg/kg (7-15 mg/kg), will be administered once daily to infants in INH arm for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Isoniazid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No INH will be administered to this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.</description>
    <arm_group_label>Isoniazid</arm_group_label>
    <other_name>INH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV exposed infants

          -  Aged 6 weeks within (+ 4 weeks)

          -  Born to HIV-infected mothers

          -  Not premature and over 2.5 kg

        Exclusion Criteria:

          -  Infants with known exposure to active TB in household

          -  Premature and &lt; 2.5 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>10 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace John-Stewart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington, Dept of Global Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grace John-Stewart, MD, PhD</last_name>
    <phone>206-543-4278</phone>
    <email>gjohn@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret Thompson, MS</last_name>
    <phone>206-543-4278</phone>
    <email>mbarrett@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kisumu County Hospital</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Kinuthia, MBChB</last_name>
      <phone>+254-722-799-052</phone>
      <email>kinuthia@u.washington.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Matemo, MDL, HND</last_name>
      <phone>+254-722-322-378</phone>
      <email>daniel.matemo@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Kinuthia, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <reference>
    <citation>Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007 Jan 20;334(7585):136. Epub 2006 Nov 3.</citation>
    <PMID>17085459</PMID>
  </reference>
  <reference>
    <citation>Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P, McSherry G, Mitchell C; P1041 Study Team. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011 Jul 7;365(1):21-31. doi: 10.1056/NEJMoa1011214.</citation>
    <PMID>21732834</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Grace John-Stewart</investigator_full_name>
    <investigator_title>Professor, Global Health, Medicine, Epidemiology, Pediatrics</investigator_title>
  </responsible_party>
  <keyword>M. tuberculosis infection</keyword>
  <keyword>isoniazid</keyword>
  <keyword>HIV-exposed infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

